Renaissance Technologies LLC Has $5.01 Million Holdings in Keros Therapeutics, Inc. $KROS

Renaissance Technologies LLC decreased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 23.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 453,482 shares of the company’s stock after selling 138,204 shares during the quarter. Renaissance Technologies LLC’s holdings in Keros Therapeutics were worth $5,006,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Canada Pension Plan Investment Board bought a new position in Keros Therapeutics during the second quarter worth $4,251,000. Caption Management LLC increased its stake in Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after purchasing an additional 291,997 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after purchasing an additional 264,445 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Keros Therapeutics by 453.9% during the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after purchasing an additional 263,347 shares during the period. Finally, Weiss Asset Management LP bought a new position in shares of Keros Therapeutics during the 4th quarter worth about $5,173,000. Institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Wells Fargo & Company reduced their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Finally, Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Keros Therapeutics currently has an average rating of “Hold” and a consensus price target of $20.50.

Keros Therapeutics Stock Performance

KROS stock opened at $10.65 on Friday. The company has a market capitalization of $211.19 million, a P/E ratio of -2.88 and a beta of 0.99. Keros Therapeutics, Inc. has a 52-week low of $9.69 and a 52-week high of $22.55. The business has a 50-day simple moving average of $10.62 and a two-hundred day simple moving average of $12.40.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.96 earnings per share for the current fiscal year.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: Wells Fargo initiated a Buy rating on Keros Therapeutics, adding a new bullish opinion that may be helping investor sentiment. Wells Fargo Issues a Buy Rating on Keros Therapeutics
• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its FY2026 EPS forecast to a loss of $4.62 from a loss of $5.12. The improved estimate is favorable relative to the firm’s prior outlook and supports the broader bullish analyst view. HC Wainwright Keros Therapeutics analyst estimates
• Neutral Sentiment: Analysts continue to describe Keros Therapeutics as attractive among healthcare stocks, but the company remains unprofitable, with a negative earnings outlook and substantial dependence on future clinical and commercial progress. Analysts Are Bullish on Top Healthcare Stocks
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS forecast to a loss of $1.49 from $1.33 and reduced estimates for FY2027 through FY2030. The cuts imply larger expected losses in those years, despite the unchanged Buy rating and $20 target. HC Wainwright revised Keros Therapeutics earnings estimates
• Negative Sentiment: Leerink Partners lowered its Keros Therapeutics price target to $23. The target remains well above recent trading levels, but the reduction signals a more cautious valuation assessment. Leerink Partners Lowers Keros Therapeutics Price Target

Insider Buying and Selling at Keros Therapeutics

In related news, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director owned 9,767 shares in the company, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,425 shares of company stock worth $89,994. Corporate insiders own 12.60% of the company’s stock.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.